Researchers clarify role of mutations in glioblastoma

July 11, 2018, University of North Carolina at Chapel Hill School of Medicine
Researchers clarify role of mutations in glioblastoma
Laboratory models with a mutated PIK3CA gene showed characteristics of gliomas. Credit: McNeill, RS, et al., PLOS ONE.

Researchers from the University of North Carolina Lineberger Comprehensive Cancer Center have discovered how different mutations in a specific gene help drive glioblastoma, the most lethal form of brain cancer.

In the preclinical study, researchers investigated whether the location of the mutation within the sequence of the PIK3CA gene affected the mutation's ability to help drive cancerous growth. They also tested whether within certain sequences of the gene were linked to better responses to particular drugs. They found mutational status was not linked to a response to a single targeted drug, but it was to a combination of treatments.

UNC Lineberger's C. Ryan Miller, MD, an associate professor in the UNC School of Medicine Departments of Pathology and Laboratory Medicine, Neurology, and Pharmacology, said the findings. published in the journal PLOS ONE, call for a more refined approach to precision medicine for glioblastoma, requiring more information about mutations that occur in a particular .

"One approach to personalized medicine has been to sequence the tumor to find any type of mutation in for which there are drugs that target them, and then treat all patients the same," Miller said. "We think it's going to need to be more nuanced than that. We will need to take into consideration not only whether there are mutations in genes like PIK3CA, but also: where the mutation is in the gene, and what is its biochemical mechanism? Not only that, but what are the other concurrent mutations in the tumor – what other genes are mutated, and are they druggable too?"

Glioblastoma is the most common primary in adults. Current treatments, which can include surgery, radiation and chemotherapy, have had limited effectiveness. A newly diagnosed patient has median survival of 12-15 months, and the five-year survival rate is less than 5 percent. Clinical trial results have been disappointing for drugs targeting certain molecular pathways driven by mutations commonly found in the disease.

Studies have found that the PIK3CA gene is mutated in about 10 percent of glioblastoma cases. Unlike some cancers in which mutations frequently occur in a specific location, or "hotspot," of a gene, mutations in PIK3CA can occur in multiple different parts of the gene in glioblastoma.

"For most of the successful examples of personalized medicine in solid tumors, the targets are hotspot mutations that activate a gene, which activates its signaling pathway, which drives the disease," Miller said. "Those tumors are addicted to that signaling. What interested us about this target is it didn't really fit that profile. The mutations were in multiple protein domains, and based on the sequence, you could predict that they would have different biochemical mechanisms of action."

In studies in glioblastoma cells, researchers found that specific mutations in the PIK3CA gene help to drive the cancer. And while the presence of mutations was not linked to a greater response to treatment with a single drug targeting the PIK3CA pathway, they did see improved response with two different therapies: buparlisib and selumetinib.

"When we did the drug studies, we found that the mutation status of the cells really didn't predict response to the drug, unless we included a second in combination that targeted a parallel pathway," Miller said.

The next step for the researchers will be to evaluate drugs targeting the particular downstream effects of the different pathways. Miller said researchers hope future studies could help identify additional potential therapeutic targets in , while helping to guide clinical trials using existing drugs.

Explore further: Newly identified genetic markers classify previously undetermined glioblastoma tumors

More information: Robert S. McNeill et al. PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition, PLOS ONE (2018). DOI: 10.1371/journal.pone.0200014

Related Stories

Newly identified genetic markers classify previously undetermined glioblastoma tumors

June 5, 2018
Most glioblastoma tumors are marked by one or two broad mutation patterns, but about 20 percent of the lethal brain tumors have biomarkers that cannot be identified. 

We may be looking at wrong mutation for breast cancer treatment

April 8, 2015
A leading gene candidate that has been the target of breast cancer drug development may not be as promising as initially thought, according to research published in open access journal Genome Medicine.

Even DNA that doesn't encode genes can drive cancer

April 2, 2018
Most of the human genome—98 percent—is made up of DNA but doesn't actually encode genes, the recipes cells use to build proteins. The vast majority of genetic mutations associated with cancer occur in these non-coding ...

From thousands of suspects, researchers ferret out cancer-causing genes

August 14, 2017
A Yale-led team of researchers has identified specific gene combinations that can cause deadly brain cancer glioblastoma, using new technology that can also pinpoint triggers of other types cancers, they report Aug. 14 in ...

Common breast cancer mutation could be vulnerable to drug combination

December 14, 2016
Breast cancer cells that carry a certain gene mutation can be induced to die using a combination of an existing targeted therapy along with an investigational molecule tested by Duke Cancer Institute researchers.

Deeper look at biopsy exposes mutation ready to ambush drug combination

March 2, 2018
A powerful resistance mutation that appeared to emerge in melanoma after a patient received a targeted therapy combination, instead was lurking in the tumor all along, primed to thwart treatment before it began, researchers ...

Recommended for you

Lung cancer drug could be repurposed to target 'zombie' proteins linked to leukemia

September 25, 2018
A new study by scientists at the University of Liverpool highlights how a clinically-approved lung cancer drug could potentially be 'repurposed' to design new treatments for future cancer therapies.

A protein called vaccinia-related kinase 1 may help cancer establish itself in new areas of the body during metastasis

September 25, 2018
Sometimes negative results can point researchers in the right direction.

Combo therapy of prostatectomy plus radiotherapy may improve survival in prostate cancer

September 25, 2018
High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective ...

Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer

September 25, 2018
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for ...

Two studies describe improved approach to bone marrow transplant

September 25, 2018
Two recent studies in the journal Leukemia present a new approach for bone marrow donation and transplant that preclinical laboratory tests suggest could make the life-saving procedure safer and more effective for patients.

Unhealthy lifestyle responsible for 45,000 predicted cases of bowel cancer in next decade

September 25, 2018
A UNSW study shows that a large proportion of bowel cancers in Australia are preventable by adopting a healthy lifestyle – particularly for men.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.